According to Arcturus Therapeutics
's latest financial reports the company has $0.29 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $0.29 B | -25.49% |
2022-12-31 | $0.39 B | 5.77% |
2021-12-31 | $0.37 B | -19.96% |
2020-12-31 | $0.46 B | 548.74% |
2019-12-31 | $71.35 M | 94.37% |
2018-12-31 | $36.7 M | -24.43% |
2017-12-31 | $48.57 M | 482.06% |
2016-12-31 | $8.34 M | -83.53% |
2015-12-31 | $50.68 M | 133.57% |
2014-12-31 | $21.69 M | -56.69% |
2013-12-31 | $50.1 M | 51552.58% |
2012-12-31 | $0.09 M | -83.04% |
2011-12-31 | $0.57 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Nymox Pharmaceutical NYMX | $0.13 M | -99.95% | Bahamas |
NRC Health
NRC | $6.65 M | -97.72% | ๐บ๐ธ USA |